Association of Interleukin-18 Gene Promoter -607 C>A and -137G>C Polymorphisms with Cancer Risk: A Meta-Analysis of 26 Studies

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yang, Xin ^a,b   Qiu, Man Tang ^a,b   Hu, Jing Wen ^a,b   Jiang, Feng ^b   Li, Ming ^b   Wang, Jie ^b   Zhang, Qin ^b   Yin, Rong ^b   Xu, Lin ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 18;

ARTICLE; ASIAN; CANCER CLASSIFICATION; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; DIGESTIVE SYSTEM CANCER; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; IL 18 GENE; NASOPHARYNX CARCINOMA; PROMOTER REGION; RISK ASSESSMENT;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-18; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84884190710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073671     Document Type: Article

References (47)

1. Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach EM, (2000) The costimulatory effect of IL-18 on the induction of antigen-specific IFN-gamma production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor beta2 subunit. Eur J Immunol 30: 1113-1119.
2. Tschoeke SK, Oberholzer A, Moldawer LL, (2006) Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 34: 1225-1233.
3. Srivastava S, Salim N, Robertson MJ, (2010) Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 17: 3353-3357.
4. Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, et al. (2002) Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 95: 663-667.
5. Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S, Tsutsui H, et al. (2002) Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother 25Suppl 1: S52-60.
6. Okano F, Yamada K, (2000) Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res 20: 3411-3415.
7. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, et al. (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167: 1644-1653.
8. Park S, Cheon S, Cho D, (2007) The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 4: 329-335.
9. Giedraitis V, He B, Huang WX, Hillert J, (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112: 146-152.
10. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, et al. (2006) Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30.
11. Farhat K, Hassen E, Bouzgarrou N, Gabbouj S, Bouaouina N, et al. (2008) Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine 43: 132-137.
12. Liu Y, Lin N, Huang L, Xu Q, Pang G, (2007) Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 26: 613-618.
13. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C, (2007) Heterozygosity for interleukin-18-607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 27: 3849-3853.
14. Wei YS, Lan Y, Liu YG, Tang H, Tang RG, et al. (2007) Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol 46: 1090-1096.
15. Qi T, Wang Q, Zheng L, Yang HL, Bao J, (2008) [Correlation of serum IL-18 level and IL-18 gene promoter polymorphisms to the risk of cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao 28: 754-757.
16. Khalili-Azad T, Razmkhah M, Ghiam AF, Doroudchi M, Talei AR, et al. (2009) Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma 56: 22-25.
17. Pan HF, Leng RX, Ye DQ, (2011) Lack of association of interleukin-18 gene promoter -607 A/C polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Lupus 20: 945-951.
18. Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, et al. (2012) Hsa-miR-499 rs3746444 Polymorphism Contributes to Cancer Risk: A Meta-Analysis of 12 Studies. PLOS ONE 7: e50887.
19. Boissel JP, Sacks HS, Leizorovicz A, Blanchard J, Panak E, et al. (1988) Meta-analysis of clinical trials: summary of an international conference. Eur J Clin Pharmacol 34: 535-538.
20. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
21. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
22. Egger M, Davey SG, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, et al. (2004) Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95: 672-679.
24. Vairaktaris E, Serefoglou ZC, Yapijakis C, Agapi C, Vassiliou S, et al. (2007) The interleukin-18-607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res 27: 4011-4014.
25. Yang HL, Pin BH, Wang Q, Zheng L, Tang W, et al. (2007) [Association of interleukin-18 gene rs1946519 and rs360718 single nucleotide polymorphism with cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao 27: 1006-1008.
26. Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V, (2008) Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res 17: 159-166.
27. Kashef MA, Dehaghani AS, Naeimi S, Fattahi MJ, Ghaderi A, (2008) Interleukin-18 gene promoter polymorphisms in women with gestational trophoblastic diseases. J Reprod Med 53: 853-859.
28. Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A, (2009) Head and neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. J Laryngol Otol 123: 444-448.
29. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, et al. (2009) IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol 24: 1119-1122.
30. Samsami DA, Shahriary K, Kashef MA, Naeimi S, Fattahi MJ, et al. (2009) Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep 36: 2393-2397.
31. Nong LG, Luo B, Zhang L, Nong HB, (2009) Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol 28: 507-513.
32. Farjadfar A, Mojtahedi Z, Ghayumi MA, Erfani N, Haghshenas MR, et al. (2009) Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol 48: 971-976.
33. Saenz-Lopez P, Carretero R, Vazquez F, Martin J, Sanchez E, et al. (2010) Impact of interleukin-18 polymorphisms-607 and-137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol 71: 309-313.
34. Monroy CM, Cortes AC, Lopez MS, D'Amelio AM Jr, Etzel CJ, et al. (2011) Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 50: 36-46.
35. Taheri M, Hashemi M, Eskandari-Nasab E, Fazaeli A, Arababi F, et al. (2012) Association of -607 C/A polymorphism of IL-18 gene (rs1946518) with breast cancer risk in Zahedan, Southeast Iran. Prague Med Rep 113: 217-222.
36. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, et al. (2012) Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol 107: 1331-1341.
37. Guo JY, Qin AQ, Li RK, Yang CM, Huang FD, et al. (2012) [Association of the IL-18 gene polymorphism with susceptibility to colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 15: 400-403.
38. Du B, Zhao J, Wei YS, (2012) Interleukin-18 gene genetic polymorphisms and risk of nasopharyngeal carcinoma in Han population from Sichuan China. Med J west China 24: 1683-1685.
39. Jaiswal PK, Singh V, Srivastava P, Mittal RD, (2013) Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene 519: 128-134.
40. Liu JM, Liu JN, Wei MT, He YZ, Zhou Y, et al. (2013) Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population. Genet Mol Res 12: 820-829.
41. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H, (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19: 423-474.
42. Gracie JA, Robertson SE, McInnes IB, (2003) Interleukin-18. J Leukoc Biol 73: 213-224.
43. Xia D, Li F, Xiang J, (2004) Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radiopharm 19: 322-330.
44. Han MY, Zheng S, Yu JM, Peng JP, Guo QS, et al. (2004) Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ Sci 5: 472-476.
45. Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY, (2005) Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst 17: 51-55.
46. Tsuboi K, Miyazaki T, Nakajima M, Fukai Y, Masuda N, et al. (2004) Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 205: 207-214.
47. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, et al. (2006) Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 12: 4473-4477.